Skip to Content

Trametinib Disease Interactions

There are 9 disease interactions with trametinib:

Moderate

Multikinase Inhibitors (Includes Trametinib) ↔ Lung Toxicity

Moderate Potential Hazard, Moderate plausibility

Applies to: Interstitial Pneumonitis, Pulmonary Impairment

The use of certain multikinase inhibitors has been associated with pulmonary toxicity. Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported. Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation. If ILD is confirmed, permanently discontinue these agents and institute appropriate measures. Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.

Moderate

Trametinib (Includes Trametinib) ↔ Cardiomyopathy

Moderate Potential Hazard, Moderate plausibility

Applies to: Cardiomyopathy, Congestive Heart Failure, Ventricular Arrhythmia

Cardiomyopathy, including cardiac failure may occur with the use of trametinib. It is recommended that all patients undergo a cardiovascular evaluation including echocardiogram at baseline to document normal left ventricular ejection fraction (LVEF) and repeat echocardiograms at Week 4, Week 12, and every 12 weeks thereafter as clinically appropriate. Withhold trametinib for up to 4 weeks if absolute LVEF value decreases by 10% from pretreatment values and is less than the lower limit of normal (LLN). Permanently discontinue trametinib for symptomatic cardiomyopathy or persistent, asymptomatic LV dysfunction of >20% from baseline that is below LLN and that does not resolve within 4 weeks.

Moderate

Trametinib (Includes Trametinib) ↔ Gi Perforation

Moderate Potential Hazard, Moderate plausibility

Applies to: Gastrointestinal Perforation, Colitis/Enteritis (Noninfectious)

Colitis and gastrointestinal perforation, sometimes with fatal outcomes can occur with the use of trametinib. Care and close monitoring is recommended with using this agent in patients with gastrointestinal complications. Monitor patients closely for colitis and gastrointestinal perforations.

Moderate

Trametinib (Includes Trametinib) ↔ Hemorrhage

Moderate Potential Hazard, Moderate plausibility

Applies to: Bleeding

The use of trametinib may increase the incidence of hemorrhagic events, including major hemorrhages defined as symptomatic bleeding in a critical area or organ. It is recommended to discontinue the use of trametinib for all Grade 4 hemorrhagic events and temporarily withhold the use of trametinib for Grade 3 hemorrhagic events, if improved, resume the dose at the next lower dose level. Close monitoring is recommended. Care should be taken when using this agent in patients at risk.

Moderate

Trametinib (Includes Trametinib) ↔ Hepatic Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Based on a population pharmacokinetic analysis of trametinib, no dose adjustment is recommended in patients with mild hepatic impairment. There are no data on the pharmacokinetics of trametinib in patients with moderate or severe hepatic impairment. Close monitoring is recommended for these patients.

Moderate

Trametinib (Includes Trametinib) ↔ Hyperglycemia

Moderate Potential Hazard, Moderate plausibility

Applies to: Diabetes Mellitus

The use of trametinib may cause hyperglycemia. It is recommended to monitor serum glucose levels upon initiation of therapy and as clinically appropriate in patients with preexisting diabetes or hyperglycemia.

Moderate

Trametinib (Includes Trametinib) ↔ Ocular Toxicities

Moderate Potential Hazard, Moderate plausibility

Applies to: Visual Defect/Disturbance

Ocular toxicities, including retinal vein occlusion (RVO), retinal pigment epithelial detachment (RPED) have been reported with the use of trametinib. It is recommended to perform ophthalmological evaluation periodically and at any time a patient reports visual disturbances. Permanently discontinue treatment with trametinib in patients with documented RVO, or RPED. Withhold therapy with trametinib if RPED is diagnosed. If resolution of the RPED is documented on repeat ophthalmological evaluation within 3 weeks, resume treatment or reduce the dose or discontinue treatment if no improvement.

Moderate

Trametinib (Includes Trametinib) ↔ Renal Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Based on a population pharmacokinetic analysis of trametinib, no dose adjustment is recommended in patients with mild or moderate renal impairment. There are no data on the pharmacokinetics of trametinib in patients with severe renal impairment. Close monitoring is recommended for these patients.

Moderate

Trametinib (Includes Trametinib) ↔ Venous Thromboembolism

Moderate Potential Hazard, Moderate plausibility

Applies to: Thrombotic/Thromboembolic Disorder

Venous thromboembolism can occur with trametinib. It is recommended to permanently discontinue the use of trametinib for life threatening pulmonary embolism and to withhold therapy for uncomplicated deep venous thrombosis and pulmonary embolism for up to 3 weeks or as clinically appropriate and if improved patients should resume treatment at a lower dose as clinically indicated. Care should be exercised when using this agent in patients at risk.

trametinib drug Interactions

There are 2 drug interactions with trametinib

trametinib alcohol/food Interactions

There is 1 alcohol/food interaction with trametinib

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide